retatrutide creator I’m Dr. Michael Richman, a double board certified cardiothoracic surgeon. In today’s video, I explain all about the novel peptide which is currently in phase 3 trials for multiple Experimental drug could offer more

Description

Statistical analysis revealed a significant reduction in redness by Week 8 ( p =0.006), with a trend towards improvement already apparent by Week 4 ( p =0.057)

Whether 50-200mg weekly produces any CNS effects is doubtful from a pharmacological perspective

This highlights how GLP-1 agonists may not only help mood symptoms but also mitigate adverse effects of current psychotropic medications, paving the way for a more holistic approach to managing bipolar disorder

Interest in the relationship between GLP-1 medications and eye health increased after researchers published a study in JAMA Ophthalmology that found a possible association between semaglutide use and NAION